SavedAdd your journal

Journals / Okmeydanı Tıp Dergisi / 2012 / Cilt: 28 - Sayı: 2

Effects of cardiometabolic risk parameters on asymmetric dimethylarginine

Kardiyometabolik risk parametrelerinin asimetrik dimetilarjinin üzerine etkileri

Aytekin ALÇELİK
Sevim KARAÇAY
Aysegül ALÇELIK
Pages
59–64
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review article we aimed to assess the associations of ADMA with these parameters.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Most of the risk factors related with atherosclerosis and cardiovascular mortality, and morbidity have been also found to be associated with endothelial dysfunction.
📊
Key Findings & Data:Concentrations of asymmetric dimethylarginine (ADMA) which are in close relation with endothelial dysfunction increase in patients with cardiovascular disease and in most of the cases which increase cardiovascular risk factors.
💡
Conclusion & Impact:In this review article we aimed to assess the associations of ADMA with these parameters.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Most of the risk factors related with atherosclerosis and cardiovascular mortality, and morbidity have been also found to be associated with endothelial dysfunction. Concentrations of asymmetric dimethylarginine (ADMA) which are in close relation with endothelial dysfunction increase in patients with cardiovascular disease and in most of the cases which increase cardiovascular risk factors. ADMA is an independent risk factor for endothelial dysfunction and congestive heart failure. Currently, ADMA has been evaluated in almost all of the cardiometabolic risk parameters. In this review article we aimed to assess the associations of ADMA with these parameters.

Özet

Ateroskleroz ve kardiyovasküler morbidite, mortaliteye ilişkin risk faktörlerinin çoğunun, endotel fonksiyonlarını bozduğu belirlenmiştir. Endotel disfonksiyonu ile yakından ilişkili olan Asimetrik dimetilarjinin (ADMA) konsantrasyonları, kardiyovasküler hastalığı olanlarda ve kardiyovasküler hastalık riskinin arttığı çoğu durumda artmaktadır. ADMA, endotel disfonksiyonu ve konjestif kalp yetmezliği için bağımsız bir risk faktörüdür. Günümüzde ADMA, kardiyometabolik risk parametrelerinin hemen hemen tümünde değerlendirilmiş bir belirteçtir. Burada ADMA’nın bu parametrelerle olan ilişkisini derlemeyi amaçladık.

🔖

Cite This Article

ALÇELİK, A., KARAÇAY, S., ALÇELIK, A. (2012). Effects of cardiometabolic risk parameters on asymmetric dimethylarginine. Okmeydanı Tıp Dergisi, Cilt: 28 - Sayı: 2, 59–64. https://ajindex.com/articles/291845

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992
  2. PMid:15908319 2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987
  3. PMid:17318075 3. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004
  4. PMid:17163402 4. Tsikas D. Analysis of the L-Arginine/Nitric Oxide Pathway: The Unique Role of Mass Spectrometry. Current Pharmaceutical Analysis 2005
  5. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmarotherapy. Phormacol Rep 2006
  6. 58(2):1734-1140. 7. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001
  7. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009
  8. Drexler H. Factors involved in the maintenance of endothelial function. Am J Cardiol 1998
  9. 82(10A):3S-4S. 10. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999
  10. Böger RH. The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 2003
  11. Vallance P, Leiper J. Cardiovascular Biology of the Asymmetric Dimethylarginine: Dimethylarginine Dimethylaminohydrolase Pathway. Arterioscler Thromb Vas Biol 2004
  12. Thum T, Tsikas D, Stein S, et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. Am Coll Cardiol 2005
  13. 46(9):1693. 14. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000
  14. Tomasian D, Keaney JF Jr, Vita JA. Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovasc Res 2000
  15. Böger RH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med 2006
  16. Leiper JM, Vallance P. The synthesis and metabolism of asymmetric dimethylarginine (ADMA). Eur J Clin Pharamacol 2005
  17. Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide synthase inhibitor: a novel marker of atheros